Brokerages Set Jasper Therapeutics, Inc. (NASDAQ:JSPR) Price Target at $73.38

Shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR) have been assigned a consensus recommendation of “Buy” from the ten ratings firms that are currently covering the company, MarketBeat reports. Ten investment analysts have rated the stock with a buy rating. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $73.38.

Several research analysts have recently commented on the company. Cantor Fitzgerald restated an “overweight” rating on shares of Jasper Therapeutics in a research report on Monday, September 9th. JMP Securities restated a “market outperform” rating and issued a $70.00 price objective on shares of Jasper Therapeutics in a report on Tuesday, October 15th. BMO Capital Markets initiated coverage on shares of Jasper Therapeutics in a research report on Friday. They issued an “outperform” rating and a $63.00 price target for the company. HC Wainwright reiterated a “buy” rating and issued a $65.00 price objective on shares of Jasper Therapeutics in a research note on Thursday, October 24th. Finally, Evercore ISI reissued an “outperform” rating and set a $65.00 price objective on shares of Jasper Therapeutics in a research report on Monday, August 26th.

Institutional Trading of Jasper Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of JSPR. Barclays PLC grew its stake in shares of Jasper Therapeutics by 320.7% in the 3rd quarter. Barclays PLC now owns 16,146 shares of the company’s stock valued at $304,000 after purchasing an additional 12,308 shares during the last quarter. Jane Street Group LLC acquired a new position in Jasper Therapeutics during the 3rd quarter valued at about $251,000. Wellington Management Group LLP acquired a new position in shares of Jasper Therapeutics during the third quarter valued at $447,000. State Street Corp raised its stake in shares of Jasper Therapeutics by 12.3% during the third quarter. State Street Corp now owns 214,883 shares of the company’s stock valued at $4,042,000 after purchasing an additional 23,564 shares in the last quarter. Finally, Samsara BioCapital LLC grew its position in Jasper Therapeutics by 11.4% during the 3rd quarter. Samsara BioCapital LLC now owns 584,642 shares of the company’s stock worth $10,997,000 after purchasing an additional 59,642 shares in the last quarter. Hedge funds and other institutional investors own 79.85% of the company’s stock.

Jasper Therapeutics Trading Down 0.4 %

Shares of JSPR opened at $22.40 on Friday. The company’s 50-day moving average price is $20.62 and its 200 day moving average price is $20.89. The firm has a market cap of $336 million, a P/E ratio of -4.73 and a beta of 2.18. Jasper Therapeutics has a 12-month low of $4.00 and a 12-month high of $31.01.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.